UBS Group’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-3,651
Closed -$104K – 10939
2026
Q1
$104K Buy
3,651
+3,352
+1,121% +$97.7K ﹤0.01% 6979
2025
Q4
$8.46K Buy
+299
New +$8.44K ﹤0.01% 8359
2024
Q1
– Sell
-1,340
Closed -$29K – 9900
2023
Q4
$29K Sell
1,340
-230
-15% -$4.75K ﹤0.01% 6862
2023
Q3
$32K Buy
1,570
+1,439
+1,098% +$30.3K ﹤0.01% 6565
2023
Q2
$2.74K Sell
131
-995
-88% -$20K ﹤0.01% 7708
2023
Q1
$22.3K Sell
1,126
-689
-38% -$13.8K ﹤0.01% 6998
2022
Q4
$35.5K Buy
1,815
+392
+28% +$7.72K ﹤0.01% 7073
2022
Q3
$25K Buy
1,423
+335
+31% +$6.57K ﹤0.01% 7102
2022
Q2
$21K Sell
1,088
-263
-19% -$5.36K ﹤0.01% 6823
2022
Q1
$29K Sell
1,351
-526
-28% -$11.1K ﹤0.01% 7037
2021
Q4
$40K Buy
+1,877
New +$39.3K ﹤0.01% 7123

Other funds holding REVS

UBS Group's REVS Position: Q2 2026 in Review

UBS Group sold out of Columbia Research Enhanced Value ETF (REVS) in Q2 2026, closing a stake of 3,651 shares — an estimated $104K sold.

UBS Group first reported a position in REVS in Q4 2021 and held it in 11 quarters. The position peaked at $104K in Q1 2026. 37 funds tracked by Wall St. Rank hold REVS as of Q2 2026.

  • UBS Group reported no remaining Columbia Research Enhanced Value ETF position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 3,651 Columbia Research Enhanced Value ETF shares in Q2 2026, an estimated $104K.
  • UBS Group first reported a position in Columbia Research Enhanced Value ETF in Q4 2021 and held it in 11 quarters.
  • UBS Group's Columbia Research Enhanced Value ETF position peaked at $104K in Q1 2026.
  • 37 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.